FEN1 overexpression is associated with an increased aggressive phenotype and poor prognosis of cancer after cisplatin chemotherapy, while inhibition of Pol β or XRCC1 can enhance the sensitivity of ovarian cancer to cisplatin treatment [16]. The gene discussed is XRCC1; the disease is ovarian carcinoma.